Goldman Sachs’s Repros Therapeutics Inc. RPRX Stock Holding History

Goldman Sachs’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3,200	Closed	-$24K	–	7717
2015 Q3	$24K	Buy	+3,200	New	+$24.5K	﹤0.01%	6996
2015 Q1	–	Sell	-70,000	Closed	-$698K	–	7649
2014 Q4	$698K	Buy	+70,000	New	+$597K	﹤0.01%	4953
2014 Q1	–	Sell	-37,800	Closed	-$692K	–	7171
2013 Q4	$692K	Sell	37,800 -115,000	-75%	-$2.17M	﹤0.01%	5052
2013 Q3	$4.09M	Sell	152,800 -496,300	-76%	-$10.6M	﹤0.01%	3156
2013 Q2	$12M	Buy	+649,100	New	+$11.5M	﹤0.01%	1937

Goldman Sachs's RPRX Position: Q1 2018 in Review

Goldman Sachs sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 11,147 shares — an estimated $7K sold.

Goldman Sachs first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $4.2M in Q2 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.

Goldman Sachs reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
Goldman Sachs sold 11,147 Repros Therapeutics Inc. shares in Q1 2018, an estimated $7K.
Goldman Sachs first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
Goldman Sachs's Repros Therapeutics Inc. position peaked at $4.2M in Q2 2013.
1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.